Identification of a tumor biomarker in advanced triple-negative breast cancer that predicts response to bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1

被引：0
|
作者：
Locke, George [1 ]
Zhang, Yue [2 ]
Ojalvo, Laureen S. [3 ]
Helwig, Christoph [4 ]
Rolfe, Alex [1 ]
Christensen, Olaf [1 ]
Dussault, Isabelle [1 ]
机构：
[1] EMD Serono Inc, Billerica, MA USA
[2] AbbVie, Waban, MA USA
[3] EMD Serono Inc, Immunooncol, Billerica, MA USA
[4] Merck KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-09-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-09-13
引用
收藏
页数：2
相关论文
共 17 条
  • [1] Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort
    Spira, Alexander
    Awada, Ahmad
    Isambert, Nicolas
    Estelles, David Lorente
    Nemunaitis, John
    Penel, Nicolas
    Ojalvo, Laureen S.
    Helwig, Christoph
    Borel, Christian
    CANCER RESEARCH, 2020, 80 (04)
  • [2] PHASE 1 EVALUATION OF BINTRAFUSP ALFA (M7824), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-β AND PD-L1, IN CERVICAL CANCER
    Allan, S.
    Braiteh, F.
    Calvo Aller, E.
    Cervantes, A.
    Edenfield, W.
    Li, T.
    Rasschaert, M.
    Park-Simon, T-W
    Longo, F.
    Paz-Ares, L.
    Spira, A.
    Strauss, J.
    Ojalvo, L. S.
    Helwig, C.
    Dussault, I.
    Gulley, J. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A72 - A73
  • [3] Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1 Plus Chemotherapy in Patients With Stage IV NSCLC
    Rolfo, Christian
    Greillier, Laurent
    Veillon, Remi
    Badin, Firas
    Ghiringhelli, Francois
    Isambert, Nicolas
    Paulus, Astrid
    Chaudhary, Surendra Pal
    Vugmeyster, Yulia
    Sato, Masashi
    Hiret, Sandrine
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (01):
  • [4] Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
    Spira, Alexander
    Awada, Ahmad
    Isambert, Nicolas
    Lorente, David
    Penel, Nicolas
    Zhang, Yue
    Ojalvo, Laureen S.
    Hicking, Christine
    Rolfe, P. Alexander
    Ihling, Christian
    Dussault, Isabelle
    Locke, George
    Borel, Christian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
    Yuehua Liang
    Xiaoran Liu
    Kun Li
    Huiping Li
    ChineseJournalofCancerResearch, 2022, 34 (02) : 117 - 130
  • [6] Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
    Liang, Yuehua
    Liu, Xiaoran
    Li, Kun
    Li, Huiping
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (02) : 117 - 130
  • [7] M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype
    Yoo, C.
    Oh, D-Y.
    Choi, H. J.
    Kudo, M.
    Ueno, M.
    Kondo, S.
    Chen, L-T.
    Osada, M.
    Helwig, C.
    Dussault, I.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Programmed death ligand 1, poly adenosine diphosphate ribose polymerase, and vascular endothelial growth factor receptor inhibition: a potential combination regimen for targeting triple-negative breast cancer?
    Abdul Wahid, Maryam
    ul Hussain, Hassan
    Ghouri, Hafsa
    Khan, Tarneem
    Rehan, Syeda Tayyaba
    Mumtaz, Hassan
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (10) : 3230 - 3233
  • [9] Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti-programmed death receptor ligand 1 therapy response of triple-negative breast cancer
    Chen, Xi
    Yan, Yuanliang
    Liu, Wangrui
    Liu, Yuanhong
    Thakur, Abhimanyu
    Liang, Qiuju
    Xu, Zhijie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (07):
  • [10] Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer
    Lee, Hong Kyu
    Ji, Hyeong-Jin
    Shin, Sang-Kyung
    Koo, Jihye
    Kim, Tae Hun
    Kim, Cho-Won
    Seong, Yeon Hee
    Park, Jun-Eui
    Choi, Kyung-Chul
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (09) : 2213 - 2226
12